[Viscometric study of secretolytically and mucolytically active inhalants]

Area of Science:

• Respiratory medicine
• Pharmacology

Background:

• Respiratory diseases often involve abnormal mucus secretion (hypercrinism, dyscrinism) and impaired clearance (mucostasis).
• Secretolytic and mucolytic agents are used to improve mucus quality, affecting its viscosity and adhesion.

Purpose of the Study:

• To evaluate the effects of specific mucolytics and secretolytics on respiratory secretion properties.
• To assess the efficacy of a novel viscosimetric device for monitoring treatment outcomes.

Main Methods:

• A nine-day inhalation therapy was administered using mucosolvin, tacholiquin, bromhexine, and saline.
• A new viscosimetric device designed for non-Newtonian liquids was employed to measure secretion changes.
• Viscosity and adhesion of respiratory secretions were quantified before and after treatment.

Main Results:

• Inhalation therapy demonstrated measurable changes in the viscosity and adhesion of respiratory secretions.
• The novel viscosimetric device proved capable of controlling and assessing the effects of secretolytic and mucolytic treatments.
• Specific agents showed varying impacts on secretion quality, indicating differential therapeutic effects.

Conclusions:

• Secretolytic and mucolytic therapies can alter respiratory secretion properties, potentially improving mucus clearance.
• The developed viscosimetric device offers a reliable method for evaluating the effectiveness of treatments targeting mucus viscosity and adhesion.
• Further research can utilize this device to optimize therapeutic strategies for respiratory conditions characterized by abnormal mucus.